Longitudinal study of humoral immunity against SARS-CoV-2 of health professionals in Brazil: the impact of booster dose and reinfection on antibody dynamics

The pandemic caused by SARS-CoV-2 has had a major impact on health systems. Vaccines have been shown to be effective in improving the clinical outcome of COVID-19, but they are not able to fully prevent infection and reinfection, especially that caused by new variants. Here, we tracked for 450 days...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 14; p. 1220600
Main Authors Franco-Luiz, Ana Paula Moreira, Fernandes, Nubia Monteiro Gonçalves Soares, Silva, Thais Bárbara de Souza, Bernardes, Wilma Patrícia de Oliveira Santos, Westin, Mateus Rodrigues, Santos, Thais Garcia, Fernandes, Gabriel da Rocha, Simões, Taynãna César, Silva, Eduardo Fernandes E, Gava, Sandra Grossi, Alves, Breno Magalhães, de Carvalho Melo, Mariana, da Silva-Pereira, Rosiane A, Alves, Pedro Augusto, Fonseca, Cristina Toscano
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 14.07.2023
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The pandemic caused by SARS-CoV-2 has had a major impact on health systems. Vaccines have been shown to be effective in improving the clinical outcome of COVID-19, but they are not able to fully prevent infection and reinfection, especially that caused by new variants. Here, we tracked for 450 days the humoral immune response and reinfection in 52 healthcare workers from Brazil. Infection and reinfection were confirmed by RT-qPCR, while IgM and IgG antibody levels were monitored by rapid test. Of the 52 participants, 19 (36%) got reinfected during the follow-up period, all presenting mild symptoms. For all participants, IgM levels dropped sharply, with over 47% of them becoming seronegative by the 60th day. For IgG, 90% of the participants became seropositive within the first 30 days of follow-up. IgG antibodies also dropped after this period reaching the lowest level on day 270 (68.5 ± 72.3, p<0.0001). Booster dose and reinfection increased the levels of both antibodies, with the interaction between them resulting in an increase in IgG levels of 130.3 arbitrary units. Overall, our data indicate that acquired humoral immunity declines over time and suggests that IgM and IgG antibody levels are not associated with the prevention of reinfection.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Edited by: William Dowling, Coalition for Epidemic Preparedness Innovations (CEPI), Norway
Reviewed by: Henning Jacobsen, Helmholtz Centre for Infection Research, Germany; Diego Cantoni, MRC-University of Glasgow Centre For Virus Research (MRC), United Kingdom
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2023.1220600